Document is current
Any future updates will be listed below
-
Authors
Fernandez, Eugenio
Vernet, Rémi
Urwyler, Muriel
Von Rohr, Olivier
Charrier, Emily
Belkouch, Marie-Claude
Saingier, Valentin
Courtout, Fabien
DeVito, Claudio
Ancrenaz, Virginie
Dulguerov, Nicolas
Karenovics, Wolfram
Grogg, Julien
Renaux, Jessica
Gobat, Katrin
Müller, Gisela
Brezina, Tomas
Rordorf, Tamara
Joerger, Markus
Michielin, Olivier
Villard, Jean
Mach, Nicolas
-
Funding
Funding for this research was provided by:
MaxiVAX SA
Horizon 2020 EIC Accelerator Programme (880194)
Innosuisse - Schweizerische Agentur für Innovationsförderung (CTI)
Gateway for Cancer Research (G-15-1700)
Krebsliga Schweiz (KLS-3867-02-2016)
Rising Tide Foundation (CCR-15-140)
Fondation Coromandel
Philanthropy Settlement
University of Geneva
- License Information
-
More Information
Article History
Received: 10 June 2025
Accepted: 19 August 2025
First Online: 31 August 2025
Declarations
:
: The study protocol was approved by the Ethics Committee of the State of Geneva (Switzerland) and Swissmedic. The study was conducted in compliance with the protocol, applicable regulatory requirements, Good Clinical Practice guidelines, and ethical principles of the latest revision of the Declaration of Helsinki, as adopted by the World Medical Association. Clinical trial identification: NCT02999646.
: Patients gave their consent for publication when signing the study inform consent form.
: N. M. is a co-founder and minority shareholder of MaxiVAX SA, now Release Therapeutics. EC and JR were former employees of MaxiVAX SA. JG is an employee of MaxiVAX SA, now Release Tx, who receives a salary in the context of his duties. MaxiVAX SA provided funding to both HUG and SAKK for supporting this study. OM has served as an advisor for Roche, Novartis, GSK, BMS, MSD, Regeneron, Pierre-Fabre, Merck, and Amgen, and is a scientific board member of Cellula Therapeutics. All the remaining authors declare that they have no conflicts of interest.
